Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:MNK
- CUSIP: N/A
- Web: www.mallinckrodt.com
- Market Cap: $4.59 billion
- Outstanding Shares: 99,346,000
- 50 Day Moving Avg: $42.97
- 200 Day Moving Avg: $47.44
- 52 Week Range: $38.80 - $85.83
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 5.49
- P/E Growth: 1.09
- Annual Revenue: $3.31 billion
- Price / Sales: 1.39
- Book Value: $51.45 per share
- Price / Book: 0.90
- EBIDTA: $744.3 million
- Net Margins: 16.01%
- Return on Equity: 16.33%
- Return on Assets: 5.48%
- Debt-to-Equity Ratio: 1.11%
- Current Ratio: 1.40%
- Quick Ratio: 1.05%
- Average Volume: 2.11 million shs.
- Beta: 1.52
- Short Ratio: 8.23
Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)
What is Mallinckrodt PLC's stock symbol?
Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How will Mallinckrodt PLC's stock buyback program work?
Mallinckrodt PLC declared that its Board of Directors has approved a stock repurchase program on Sunday, April 9th 2017, which authorizes the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 18.5% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its stock is undervalued.
How were Mallinckrodt PLC's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) posted its quarterly earnings results on Monday, May, 8th. The company reported $1.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.63 by $0.05. The firm had revenue of $810.90 million for the quarter, compared to analyst estimates of $781.23 million. Mallinckrodt PLC had a net margin of 16.01% and a return on equity of 16.33%. Mallinckrodt PLC's revenue for the quarter was down .6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.01 EPS. View Mallinckrodt PLC's Earnings History.
Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?
17 equities research analysts have issued 12 month price objectives for Mallinckrodt PLC's shares. Their forecasts range from $52.00 to $98.00. On average, they anticipate Mallinckrodt PLC's stock price to reach $76.26 in the next twelve months. View Analyst Ratings for Mallinckrodt PLC.
What are analysts saying about Mallinckrodt PLC stock?
Here are some recent quotes from research analysts about Mallinckrodt PLC stock:
- 1. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
- 2. According to Zacks Investment Research, "Mallinckrodt reported strong results for the transition quarter (Oct 1 to Dec 30) beating both sales and earnings expectations. The results were driven by volume-based growth across its Specialty Brands segment which once more offset the ongoing challenges in Specialty Generics segment. Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to lingering challenging conditions for quite some time. The company also announced to sell its Intrathecal Therapy business. Meanwhile, Mallinckrodt acquire-to-invest policy is apparently paying off as both Inomax and Therakos continue to witness solid demand along with Ofirmev. The performance of Acthar has been impressive too. Estimates for 2017 have gone up post the strong results. However, shares have underperformed the Medical-Generic Drugs industry in 2017." (2/9/2017)
- 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)
Who are some of Mallinckrodt PLC's key competitors?
Some companies that are related to Mallinckrodt PLC include ConvaTec Group PLC (CTEC), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), Eagle Pharmaceuticals (EGRX), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Mallinckrodt PLC's key executives?
Mallinckrodt PLC's management team includes the folowing people:
- Melvin D. Booth Ph.D., CPA, Independent Chairman of the Board
- Mark C. Trudeau, President, Chief Executive Officer, Director
- Matthew K. Harbaugh, Chief Financial Officer, Senior Vice President
- Ian J. Watkins, Chief Human Resource Officer, Senior Vice President
- Steve Romano, Senior Vice President, Chief Scientific Officer
- Raymond J. Furey, Senior Vice President, Chief Compliance Officer
- Terrance L. Carlson, Senior Vice President and General Counsel - Interim
- Meredith B. Fischer, Senior Vice President - Communications and Public Affairs
- Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases
- Gary M. Phillips M.D., Senior Vice President and Chief Strategy Officer
Who owns Mallinckrodt PLC stock?
Mallinckrodt PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.79%), BlackRock Inc. (8.34%), Paulson & CO. Inc. (7.55%), State Street Corp (5.23%), Alliancebernstein L.P. (2.77%) and Prudential Financial Inc. (1.85%). Company insiders that own Mallinckrodt PLC stock include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Institutional Ownership Trends for Mallinckrodt PLC.
Who sold Mallinckrodt PLC stock? Who is selling Mallinckrodt PLC stock?
Mallinckrodt PLC's stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Janus Capital Management LLC, Morgan Stanley, Paulson & CO. Inc., Cornerstone Capital Management Holdings LLC., JPMorgan Chase & Co., FMR LLC and Westpac Banking Corp. View Insider Buying and Selling for Mallinckrodt PLC.
Who bought Mallinckrodt PLC stock? Who is buying Mallinckrodt PLC stock?
Mallinckrodt PLC's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Alliancebernstein L.P., Hotchkis & Wiley Capital Management LLC, Bank of America Corp DE, Legal & General Group Plc, Ameriprise Financial Inc., State Street Corp and Acadian Asset Management LLC. Company insiders that have bought Mallinckrodt PLC stock in the last two years include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Insider Buying and Selling for Mallinckrodt PLC.
How do I buy Mallinckrodt PLC stock?
Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt PLC's stock price today?
MarketBeat Community Rating for Mallinckrodt PLC (NYSE MNK)MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Mallinckrodt PLC stock can currently be purchased for approximately $46.24.
Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 15 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.88)|
|Consensus Price Target: ||$76.26 (64.93% upside)|
Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
(Data available from 6/27/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/21/2017||Wells Fargo & Company||Reiterated Rating||Outperform||$83.50||High|
|6/20/2017||Jefferies Group LLC||Reiterated Rating||Buy||$70.00||High|
|6/16/2017||Cantor Fitzgerald||Initiated Coverage||Overweight -> Overweight||$52.00||Low|
|5/31/2017||Morgan Stanley||Set Price Target||Buy||$65.00||Low|
|5/31/2017||Deutsche Bank AG||Set Price Target||Buy||$68.00||Low|
|5/10/2017||BMO Capital Markets||Lower Price Target||Outperform||$79.00 -> $69.00||Medium|
|5/9/2017||Canaccord Genuity||Lower Price Target||Buy -> Buy||$91.00 -> $87.00||Medium|
|4/1/2017||Guggenheim||Set Price Target||Buy||$98.00||Low|
|3/20/2017||Leerink Swann||Reiterated Rating||Outperform||Low|
|2/8/2017||Piper Jaffray Companies||Lower Price Target||Overweight||$108.00 -> $83.00||N/A|
|1/25/2017||JPMorgan Chase & Co.||Set Price Target||Hold||$78.00||N/A|
|1/19/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$72.00||N/A|
|11/18/2016||Raymond James Financial, Inc.||Initiated Coverage||Outperform||$72.00||N/A|
|8/26/2016||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Neutral||$83.00||N/A|
|8/25/2016||Barclays PLC||Reiterated Rating||Overweight||$88.00||N/A|
|8/12/2016||Stifel Nicolaus||Initiated Coverage||Buy||$95.00||N/A|
|3/16/2016||Northland Securities||Reiterated Rating||Buy||$95.00||N/A|
|10/7/2015||Bank of America Corporation||Lower Price Target||Buy||$135.00 -> $131.00||N/A|
Earnings History for Mallinckrodt PLC (NYSE:MNK)Earnings History by Quarter for Mallinckrodt PLC (NYSE MNK)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/8/2017||Q1 2017||$1.63||$1.68||$781.23 million||$810.90 million||View||Listen|
|2/7/2017||Q117||$1.82||$1.91||$827.12 million||$829.90 million||View||Listen|
|11/29/2016||Q416||$1.98||$2.04||$880.10 million||$887.20 million||View||Listen|
|8/2/2016||Q316||$2.01||$2.20||$920.35 million||$970.60 million||View||Listen|
|5/3/2016||Q216||$1.72||$2.01||$878.70 million||$918.00 million||View||Listen|
|2/2/2016||Q116||$1.78||$2.09||$888.33 million||$915.00 million||View||Listen|
|11/23/2015||Q415||$1.77||$1.84||$869.41 million||$882.40 million||View||Listen|
|8/4/2015||Q315||$1.82||$2.05||$983.81 million||$965.10 million||View||Listen|
|5/5/2015||Q215||$1.48||$1.72||$860.89 million||$909.90 million||View||Listen|
|2/3/2015||Q115||$1.57||$1.84||$880.12 million||$866.00 million||View||Listen|
|11/19/2014||Q414||$1.41||$1.68||$759.04 million||$789.00 million||View||Listen|
|8/7/2014||Q314||$0.86||$1.20||$278.80 million||$653.10 million||View||Listen|
|5/8/2014||Q214||$0.79||$0.95||$566.50 million||$557.80 million||View||Listen|
|2/6/2014||Q1||$0.66||$0.88||$539.24 million||$540.20 million||View||Listen|
|11/7/2013||$0.85||$1.02||$572.57 million||$552.20 million||View||Listen|
|8/9/2013||Q3 2013||$0.78||$0.49||$557.22 million||$570.00 million||View||Listen|
Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
2017 EPS Consensus Estimate: $7.58
2018 EPS Consensus Estimate: $8.53
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE:MNK)
Insider Ownership Percentage: 0.53%Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Institutional Ownership Percentage: 96.46%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/9/2017||Steven J. Romano||VP||Buy||1,000||$39.88||$39,880.00|| |
|6/8/2017||Hugh M. O'neill||VP||Buy||1,000||$40.24||$40,240.00|| |
|6/5/2017||Coleman N Lannum III||VP||Buy||500||$39.33||$19,665.00|| |
|6/2/2017||Coleman N Lannum III||VP||Buy||1,350||$42.89||$57,901.50|| |
|5/12/2017||Coleman N. Lannum III||VP||Buy||1,968||$46.20||$90,921.60|| |
|3/10/2017||Matthew K. Harbaugh||CFO||Buy||600||$49.19||$29,514.00|| |
|3/7/2017||Michael-Bryant Hicks||General Counsel||Buy||290||$50.35||$14,601.50|| |
|2/23/2017||Meredith B. Fischer||Insider||Buy||2,000||$54.34||$108,680.00|| |
|2/14/2017||Mark Trudeau||Insider||Buy||1,000||$50.47||$50,470.00|| |
|2/10/2017||Steven J. Romano||VP||Buy||1,000||$49.68||$49,680.00|| |
|5/10/2016||Hugh M O'neill||VP||Buy||1,653||$60.99||$100,816.47|| |
|5/10/2016||Matthew K Harbaugh||CFO||Buy||500||$59.37||$29,685.00|| |
|5/6/2016||Mark Trudeau||CEO||Buy||1,000||$56.02||$56,020.00|| |
|5/6/2016||Steven J Romano||VP||Buy||900||$56.00||$50,400.00|| |
|3/4/2016||Coleman N Lannum III||VP||Buy||2,600||$62.63||$162,838.00|| |
|2/26/2016||Meredith B Fischer||VP||Buy||1,400||$69.80||$97,720.00|| |
|2/12/2016||Coleman N Lannum III||VP||Buy||600||$59.66||$35,796.00|| |
|2/10/2016||Coleman N Lannum III||VP||Buy||1,300||$62.58||$81,354.00|| |
|2/9/2016||Matthew K. Harbaugh||CFO||Buy||1,300||$63.00||$81,900.00|| |
|2/8/2016||Coleman N. Lannum III||VP||Buy||800||$66.37||$53,096.00|| |
|12/22/2015||Coleman N Lannum III||SVP||Buy||500||$72.50||$36,250.00|| |
|12/11/2015||Terrance L Carlson||General Counsel||Buy||1,000||$69.10||$69,100.00|| |
|12/2/2015||Gary M. Phillips||VP||Buy||1,000||$72.17||$72,170.00|| |
|11/30/2015||Mark Trudeau||CEO||Buy||1,350||$65.89||$88,951.50|| |
|11/27/2015||Coleman N Lannum III||SVP||Buy||1,200||$66.86||$80,232.00|| |
|11/27/2015||Meredith B Fischer||VP||Buy||2,200||$66.93||$147,246.00|| |
|11/27/2015||Terrance L Carlson||General Counsel||Buy||1,000||$66.54||$66,540.00|| |
|8/25/2015||Hugh M O'neill||SVP||Buy||1,197||$83.52||$99,973.44|| |
|8/25/2015||Mark Trudeau||CEO||Buy||1,000||$83.08||$83,080.00|| |
|8/21/2015||Coleman N Lannum III||SVP||Buy||2,375||$88.52||$210,235.00|| |
|8/21/2015||Mark Trudeau||CEO||Buy||2,000||$88.45||$176,900.00|| |
|6/4/2015||Coleman N Lannum III||VP||Buy||1,300||$126.41||$164,333.00|| |
|6/2/2015||Matthew K Harbaugh||CFO||Sell||22,106||$128.64||$2,843,715.84|| |
|5/18/2015||Mario D Saltarelli||VP||Sell||4,580||$127.44||$583,675.20|| |
|5/13/2015||Don M Bailey||Director||Sell||51,417||$122.45||$6,296,011.65|| |
|5/11/2015||Sandra L Hatten||VP||Sell||2,024||$122.29||$247,514.96|| |
|4/13/2015||Don M Bailey||Director||Sell||40,000||$127.61||$5,104,400.00|| |
|3/13/2015||Don M Bailey||Director||Sell||40,000||$123.40||$4,936,000.00|| |
|2/13/2015||Don M Bailey||Director||Sell||33,891||$114.63||$3,884,925.33|| |
|2/2/2015||Mark Trudeau||CEO||Sell||11,925||$105.94||$1,263,334.50|| |
|1/9/2015||Mark Trudeau||CEO||Sell||15,720||$102.00||$1,603,440.00|| |
|12/22/2014||Peter G Edwards||VP||Sell||1,265||$99.69||$126,107.85|| |
|12/18/2014||Mark Trudeau||CEO||Sell||13,831||$93.59||$1,294,443.29|| |
|9/10/2014||Raymond J Furey||VP||Sell||5,441||$85.90||$467,381.90|| |
|9/8/2014||Don M Bailey||Director||Sell||221,177||$85.23||$18,850,915.71|| |
|9/5/2014||Raymond J Furey||VP||Sell||15,000||$85.47||$1,282,050.00|| |
|9/5/2014||Virgil D Thompson||Director||Sell||25,000||$83.76||$2,094,000.00|| |
|9/2/2014||Raymond J Furey||VP||Sell||10,303||$81.61||$840,827.83|| |
|8/29/2014||Raymond J Furey||VP||Sell||4,840||$80.90||$391,556.00|| |
|8/19/2014||Joseph A Zaccagnino||Director||Buy||3,000||$71.06||$213,180.00|| |
|8/13/2014||Paulson & Co Inc||Major Shareholder||Buy||132,100||$69.80||$9,220,580.00|| |
|8/12/2014||J Martin Carroll||Director||Buy||2,000||$69.24||$138,480.00|| |
|8/12/2014||Paulson & Co Inc||Major Shareholder||Buy||467,900||$68.78||$32,182,162.00|| |
|8/11/2014||Paulson & Co Inc||Major Shareholder||Buy||207,900||$69.70||$14,490,630.00|| |
|8/7/2014||Paulson & Co Inc||Major Shareholder||Buy||700,200||$70.15||$49,119,030.00|| |
|8/1/2014||Paulson & Co Inc||Major Shareholder||Buy||275,000||$69.60||$19,140,000.00|| |
|6/11/2014||Melvin D Booth||Director||Buy||4,000||$76.05||$304,200.00|| |
|5/9/2014||Paulson & Co Inc||major shareholder||Buy||786,207||$73.63||$57,888,421.41|| |
|2/3/2014||Mark Trudeau||CEO||Sell||14,890||$56.12||$835,626.80|| |
Headline Trends for Mallinckrodt PLC (NYSE:MNK)
Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
Mallinckrodt PLC (MNK) Chart for Tuesday, June, 27, 2017